Merging company

FTC orders 2 generics sold under $ 210 million pharmaceutical deal


By Christopher Cole (Nov 10, 2021, 7:35 p.m. EST) – Two pharmaceutical companies must sell their stakes in a generic drug pair and seek Federal Trade Commission approval for any future entry into those drug markets to complete their $ 210 million merger, the FTC said on Wednesday.

ANI Pharmaceuticals Inc. and Novitium Pharma LLC are required under the proposed consent agreement to transfer their interests in the drugs to Prasco LLC in order to maintain competition as ANI acquires the other company as part of an agreement unveiled in March. Generics are used to treat infections and inflammation.

Both drugs – generic sulfamethoxazole-trimethoprim oral suspension, or SMX-TMP, and generic dexamethasone …

Stay one step ahead

In the legal profession, information is the key to success. You need to know what’s going on with customers, competitors, practice areas, and industries. Law360 provides the intelligence you need to stay an expert and beat the competition.

  • Access to case data in articles (numbers, filings, courts, nature of prosecution, etc.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, requests, etc.
  • Create personalized alerts for specific case articles and topics and more!



Leave a Reply

Your email address will not be published.